← board
SNTI
Senti Biosciencesdistress 5/10 · elevated risk$0.46+3%today-81% from 52w high
Oncology 1
Lead: relapsed/refractory hematologic malignancies including AML
Revenue
pre-revenue
Liquidity
$9M
Runway
0.2 yrs
Shares 1y
+19%
Price & events
-60.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.2%
1D
-1.1%
1W
-50.8%
1M
-54.9%
3M
-57.9%
6M
-77.8%
1Y
-80.6%
2Y
-99.5%
5Y
-99.5%
All
Overview
- Market Cap
- $14.17M
- Volume
- 13.96K
- 52 Week Range
- $0.43 – $2.39
- Total Shares
- 31.14M
- Float Shares
- 12.45M
- Short %
- 3.12%
- % Held by Insiders
- 47.91%
- % Held by Institutions
- 18.54%
- RVOL
- 0.05x
- Beta
- 2.05
Pipeline stages · 1 programs
SENTI-202
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-02 | Phase 1 | SENTI-202rmatorphan | AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies | 21 | active not recruiting |
Catalyst news & presentations · 4
- 2025readoutPhase 1SENTI-202 · Initial durability dataSEC 8-K
- fourth quarter of 2024trial initiationsecondarySENTI-301A · Dose first patient in pilot trial in ChinaSEC 8-K
- by year-end 2024readoutPhase 1SENTI-202 · Initial efficacy dataSEC 8-K
- December 16, 2024trial initiationsecondaryPhase 1SN301A · First patient dosed in dose-finding trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $13 (+2757% upside) · 3 analysts
- 2026-05-15Chardan CapitalBuy
- 2026-03-30Chardan CapitalBuy
- 2025-12-09Chardan CapitalBuy
- 2025-11-21Leerink PartnersOutperform
- 2025-10-14HC Wainwright & Co.Buy
- 2025-08-08Chardan CapitalBuy
Competitors — relapsed/refractory hematologic malignancies including AML
- none identified
Recent news
- 2026-07-21Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
- 2026-07-21Senti Biosciences (SNTI) outlines CVR-only merger, reverse split and note share issuance - Stock Titan
- 2026-07-17Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com - Investing.com Nigeria
- 2026-07-16Form S-3/A Senti Biosciences Holdings Inc For: 16 July - Investing.com Nigeria
- 2026-07-16Senti Biosciences (SNTI) backer plans merger and $6M funding - Stock Titan
- 2026-07-16Senti Biosciences (SNTI) resale, notes and merger reshape control - Stock Titan
- 2026-07-15Senti Biosciences to spin off gene therapy unit for CVR - Investing.com
- 2026-07-15Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform - Quiver Quantitative
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.